- Home
- MTEN vs IMUX Comparison
MTEN vs IMUX Comparison
Compare MTEN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEN
- IMUX
- Stock Information
- Founded
- MTEN 2015
- IMUX 2016
- Country
- MTEN China
- IMUX United States
- Employees
- MTEN N/A
- IMUX N/A
- Industry
- MTEN Building Products
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- MTEN Industrials
- IMUX Health Care
- Exchange
- MTEN Nasdaq
- IMUX Nasdaq
- Market Cap
- MTEN 97.9M
- IMUX 107.3M
- IPO Year
- MTEN 2024
- IMUX N/A
- Fundamental
- Price
- MTEN $12.27
- IMUX $0.70
- Analyst Decision
- MTEN
- IMUX Strong Buy
- Analyst Count
- MTEN 0
- IMUX 6
- Target Price
- MTEN N/A
- IMUX $11.60
- AVG Volume (30 Days)
- MTEN 84.1K
- IMUX 1.4M
- Earning Date
- MTEN 04-30-2025
- IMUX 05-15-2025
- Dividend Yield
- MTEN N/A
- IMUX N/A
- EPS Growth
- MTEN N/A
- IMUX N/A
- EPS
- MTEN N/A
- IMUX N/A
- Revenue
- MTEN $10,120,257.00
- IMUX N/A
- Revenue This Year
- MTEN N/A
- IMUX N/A
- Revenue Next Year
- MTEN N/A
- IMUX N/A
- P/E Ratio
- MTEN N/A
- IMUX N/A
- Revenue Growth
- MTEN 23.03
- IMUX N/A
- 52 Week Low
- MTEN $1.81
- IMUX $0.56
- 52 Week High
- MTEN $16.60
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- MTEN N/A
- IMUX 31.04
- Support Level
- MTEN N/A
- IMUX $0.56
- Resistance Level
- MTEN N/A
- IMUX $0.95
- Average True Range (ATR)
- MTEN 0.00
- IMUX 0.07
- MACD
- MTEN 0.00
- IMUX -0.03
- Stochastic Oscillator
- MTEN 0.00
- IMUX 30.28
About MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides a wide range of products including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in automobile, construction machinery, and other manufacturing industries.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.